In Israel, a new blood test for the early diagnosis of Alzheimer’s disease has been introduced and added to the diagnostic criteria of the International Alzheimer’s Association. The test, which is performed in addition to spinal fluid tests already available in several hospitals, aims to diagnose the disease as early as possible, even before symptoms appear. With this new tool, doctors hope to potentially delay the progression of the disease by starting treatment earlier.
Alzheimer’s disease is a degenerative condition that affects approximately 120,000 people in Israel. Symptoms include memory loss, deterioration in mental function, and damage to cognitive abilities. Patients may also experience hypervigilance, hallucinations and insomnia. Currently, diagnosis is based on symptoms and some hospitals are incorporating tests for disease proteins in spinal fluid into the diagnostic process.
In the USA, a new blood test has been approved for diagnosing Alzheimer’s disease based on specific proteins found in the bloodstream. This test is now being performed in some Israeli hospitals as well. The international recommendations for diagnosis through this blood test have been added to the criteria for diagnosing Alzheimer’s disease marking a significant step forward in improving treatment options for patients.
Professionals believe that early diagnosis through accurate blood tests could revolutionize treatment of Alzheimer’s disease. With the ability to detect it years before symptoms appear, individuals may have an opportunity to receive early treatment or make lifestyle changes that can slow down or even prevent further progression of this debilitating condition. This shift towards more accurate diagnosis based on biomarkers represents a major advancement in Alzheimer’s research and offers hope for those affected by this devastating illness.